Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1108 clinical trials
featured
A Washington University research study is currently enrolling participants with diagnosed primary immunodeficiency disorder (PID).

The purpose of the research study is to find out if the COVID – 19 vaccine can produce an immune response in patients with PID. The study will also look at genetic factors that determine response. 

  • 10 views
  • 11 May, 2021
  • 1 location
featured
A Washington University research study is currently enrolling participants with primary Immune deficiency (PID). IRB ID #: 201910008

The purpose of this research study is to investigate different ways to dose with CUTAQUIG ® in patients suffering from primary Immune deficiency (PID).

immunodeficiency
immune deficiency
immune disorder
primary immunodeficiency
immune disorders
  • 0 views
  • 25 Jan, 2021
  • 1 location
featured
MACS/WIHS Combined Cohort Study

A collaborative research study that aims to understand co-morbidities and chronic health conditions among men and women living with HIV.

  • 0 views
  • 12 Apr, 2021
  • 1 location
featured
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 74 views
  • 25 Mar, 2021
  • 1 location
featured
EMR200147-501 Title A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects with HIV-Associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for injection) to a Similar Group of Subjects not Exposed to EGRIFTA®

EMR200147-501 Title A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects with HIV-Associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for injection) to a Similar Group of Subjects not Exposed to EGRIFTA®

  • 276 views
  • 23 Nov, 2020
  • 1 location
featured
TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

  • 144 views
  • 08 Nov, 2020
  • 1 location
featured
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 182 views
  • 25 Mar, 2021
  • 1 location
featured
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

  • 82 views
  • 25 Mar, 2021
  • 1 location
featured
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)

  • 674 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

  • 167 views
  • 08 Nov, 2020
  • 1 location